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Our objective was to evaluate outcomes in patients with sustained viral suppression compared to those with episodes of viremia.
Methods. In a prospective cohort of patients started on ART in Uganda and followed for 48 months, patients were categorized
according to viral load (VL): (1) sustained-suppression: (VL ≤1,000 copies/mL) (2) VL 1,001–10,000, or (3) VL >10,000. Results.
Fifty-Three (11.2%) and 84 (17.8%) patients had a ﬁrst episode of intermediate and high viremia, respectively. Patients with
sustained suppression had better CD4+ T cell count increases over time compared to viremic patients (P<. 001). The majority of
patients with viremia achieved viral suppression when the measurement was repeated. Only 39.6% of patients with intermediate
and19.1% withhigh viremiaeventually needed to be switched tosecondline (P = .008).Conclusions. The use ofat leastonerepeat
measurement rather than a single VL measurement could avert from 60% to 80% of unnecessary switches.
1.Introduction
Data from developed countries suggest that episodes of
low (400–1000 copies/mL) and transient viremia while on
antiretroviral treatment(ART)havelimitedconsequenceson
patients’ clinical and immunological outcomes and have a
low risk of developing drug resistance [1–4], while episodes
of viremia >1,000 copies/mL have been associated with
new clinical events [5]. The optimal threshold at which
patients should be switched to second line is still debated.
It has been reported that patients may not have detrimental
eﬀects on CD4 T-cell counts [6] and clinical progression
of disease [7] despite having detectable viral load (VL)
above 10,000copies/mL. The 2006 World Health Organiza-
tion (WHO) guidelines recommended switching patients to
second-line ART if the VL was >10,000copies/mL. There-
fore, patients with VL between 1000 and 10,000 copies/mL
were usually maintained on ﬁrst-line treatment and no
speciﬁc guidance was available to clinicians [8]. Recently
the WHO published a document [9] recommending that
patients with a VL >5,000 copies/mL should have a VL
repeated and, if the VL remains >5,000 copies/mL, should
prompt therapy change.
The objective of our study was to evaluate clinical,
immunological, virological, and therapeutic outcomes in
patients with sustained viral suppression compared to
patients with ﬁrst episodes of viremia (categorized by
magnitude) after at least 6 months of ART.
2.Methods
We analyzed data from a prospective cohort of patients
started on ﬁrst-line ART between April 2004 and April 2005
and followed for 4 years at the Infectious Diseases Insti-
tute, Kampala, Uganda. Patients were started on stavudine,
lamivudine, and nevirapine (provided by Global Fund), or
on zidovudine plus lamivudine plus efavirenz (provided by
the US President’s Emergency Plan for AIDS Relief).
A detailed description of the study has been published
elsewhere [10]. Brieﬂy, the study subjects are assessed2 AIDS Research and Treatment
clinically every 3 months and laboratory testing including
CD4+ T-cell count by FACS Count (Becton Dickinson,
Mountain View, California, USA), and HIV-1 VL (Amplicor
HIV-1 Monitor PCR Test, version 1.5, Roche Diagnostic,
GmbH Molecular Systems, Pleasanton, California, USA),
with a detection limit of 400 copies/mL is performed every 6
months. The study was approved by the Institutional Review
Board of Makerere University Faculty of Medicine and the
Uganda National Council for Science and Technology (no:
MV 853).
Patients were included in the analysis if they had reached
6 months of followup on ART. They were categorized
according to VL measurements: (1) subjects with sustained
suppression: (VL ≤1,000 copies/mL at each measurement),
(2) subjects with a ﬁrst episode of intermediate viremia (VL
between1,001–10,000copies/mL), or(3)subjects witha ﬁrst
episode of high viremia (VL >10,000 copies/mL). We also
recategorized patients with a ﬁrst episode ofviremia between
1,000–5,000 copies/mL and those with a ﬁrst episode of
viremia >5,000 copies/mL for a second analysis according to
the new WHO recommendation.
Clinical outcome was deﬁned as the occurrence of
new opportunistic infections or death after reaching a ﬁrst
episode of viremia. Immunological outcome was deﬁned as
the median increase in CD4+ T-cell count at the end of the
study and the cumulative probability of reaching a CD4+ T-
cell count of 200 cells/µL in patients that had not reached
200 cell/µL at month 6. The virological outcome was deﬁned
as the proportions of patients with a consecutive subsequent
VL ≤1,000, 1,000–10,000 and >10,000 copies/mL. Finally,
the therapeutic outcome was deﬁned as the proportion of
patients switched to second line. The standard operating
procedure in our clinic for patients with episodes of viremia
is to switch patient with 2 consecutive VL >1,000 copies/mL.
However, in clinical practice patients are often not switched
after 2 consecutive VLs >1,000 copies/mL. This is due to a
variety of reasons: clinician reluctance to switch patients due
to the lack of subsequent treatment options, subsequent low
measures (<10,000) of detectable VLs, and ﬁnally irregular
supply of the second-line drugs.
2.1. Statistical Analysis. We compared the baseline charac-
teristics of patients in diﬀerent VL groups. We compared
baseline characteristics using the Kruskal Wallis test for
continuous variables (age, body mass index, hemoglobin,
CD4+ count) and chi-square for categorical variables (gen-
der, WHO staging, ART regimen).
We used the Kruskal Wallis test to compare median
CD4+ T-cell count increase at followup, chi-square tests
to compare proportion of outcomes and proportion of
patients that did not achieve a CD4+ T-cell count number
>200cell/µLatmonth6,andKaplanMaiercurvestodescribe
the probability of reaching a CD4+ T cell count >200 cell/µL
in patients with a CD4+ T cell count ≤200 cell/µLa f t e r6
months of followup.
3.Results
Of the 559 patients enrolled in the study, 474 reached at
least 6 months on ART; of thesep a t i e n t s ,o n ep a t i e n th a d
no VL measurement available after 6 months on ART, and
therefore, 473 (84.6%) were included the analysis. Sixty-
seven died [11], 13 were lost to followup, 4 were transferred
other facilities, and 1 withdrew consent before reaching 6
months on ART. The patients were followed up for a median
time of 48 months (range 6–48).
3.1. Baseline Characteristics and Patients Classiﬁcation. The
majority of the patients (n = 336, 71%) had sustained
suppression throughout the study, 53 (11.2%) patients
had a ﬁrst episode of intermediate viremia (1,000–10,000
copies/mL) after a median time of 40 weeks (IQR 26–74)
and 84 (17.8%) patients had a ﬁrst episode of high viremia
(>10,000 copies/mL) after a median time of 48 weeks (IQR
28–74) (P = .624).
T h eb a s e l i n ec h a r a c t e r i s t i c sw e r es i m i l a ri nt h et h r e e
groups except that a higher proportion (90.6%) of patients
with a ﬁrst episode of intermediate viremia were started
on an nevirapine-based regimen as compared to patients
with sustained suppression (71.7%) and patients with a ﬁrst
episode of high viremia (72.6%) (P = .009) (Table 1).
3.2. Opportunistic Infections and Death. We did not observe
diﬀerences in the proportion of deaths in patients with
sustained suppression (6.9%) compared to patients with
a ﬁrst episode of intermediate (5.7%) and high viremia
(11.9%) (P = .25).
The proportion of patients experiencing at least one
WHO grade 3 or 4 clinical event after 6 months of ART
was similar in the three groups (21.1% (sustained), 28.2%
(intermediate viremia), and 24.5% (high viremia) P = .4).
A similar proportion of patients with a ﬁrst episode of
intermediate and high viremia experienced an opportunistic
infection before (22.6% versus 27.4%, P = .53) and after the
episode of viremia (7.5% versus 8.3%, P = .866).
3.3. Immunologic Response. The median CD4+ T-cell count
increase at diﬀerent study intervals was higher in patients
with sustained suppression compared to those patients with
intermediate and high viremia (P = .001) with a total
increase at year 4 (or at the last available observation) of 186
cells/µL, 167 cells/µL, and 107 cells/µL, resp. (Figure 1(a)).
Overall, 220 (46.4%) patients did not achieve a CD4+ T-
cell count >200 cells/µL at month 6. Only 42.9% (144/336)
of those patients who achieved sustained suppression did
not achieve a CD4+ T-cell count >200 cells/µL, compared to
58.5%(31/53)and53.6%(39/84)ofthosewithaﬁrstepisode
of intermediate and high viremia, respectively (P = .033). In
the patients that had not achieved this threshold by month
6, the probability of achieving >200 cells/µLb yy e a r4w a s
higher in the patients with sustained suppression (86.8%)
and the patients with a ﬁrst episode of intermediate viremia
(96.8%) compared to the patients with a ﬁrst episode ofhigh
viremia (55.6%) (P = .017) (Figure 1(b)).AIDS Research and Treatment 3
Table 1: Comparison of the baseline characteristics of 473 patients classiﬁed in three groups according to their level of viremia.
Patients characteristics Sustained suppression∗
336 (71.0%)
Intermediate viremia∗
53 (11.2)
High viremia∗
84 (17.8) P value
Female, number (%) 240 (71.4) 30 (56.6) 56 (66.7) .085
Age (years), median (IQR) 35 (30–42) 34 (30–42) 34 (28–38.5) .168
CD4+ count median cell/µL
(IQR) 107 (35–174) 85 (25–154) 89.5 (26–165) .246
BMI (Kg/m2), median IQR 20.1 (18.3–22.5) 20.6 (18.5–20.5) 20.0 (18–22.5) .816
WHO Stage3 and 4, number (%) 291 (86.6) 51 (96.2) 76 (90.5) .102
Hemoglobin median g/dL (IQR) 11.7 (10.4–13) 11.9 (10.8–13.2) 11.6 (10.5–13) .792
ART, number (%)
Nevirapine 241 (71.7) 48 (90.6) 61 (72.6) .009
Efavirenz 95 (28.3) 5 (9.4) 23 (27.4)
∗Patients were categorized according to viral load measurements after 6 months on treatment. (1) Sustained suppression. Viral load ≤1,000 copies/mL at
each measurement. (2) Subjects with a ﬁrst episode of intermediate viremia. Viral load between 1,001–10,000copies/mL. (3) Subjects with a ﬁrst episode of
high viremia. Viral load >10,000 copies/mL.
BMI: body mass index; ART: antiretroviral treatment; IQR: interquartile range.
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Figure 1: (a) Median increase in CD4+ T-cell count in patient with sustained suppression (viral load VL ≤1,000copies/mL at each
measurement), patients with a ﬁrst episode of intermediate viremia (viral load between 1,001–10,000copies/mL), and high viremia (viral
load >10,000 copies/mL) over time. (b) Probability of achieving CD4+ T-cell count >200 cells/µL in patient with sustained suppression
(viral load VL ≤1,000 copies/mL at each measurement), patients with a ﬁrst episode of intermediate viremia (viral load between 1,001–
10,000 copies/mL, and high viremia (viral load >10,000 copies/mL) over time.
3.4. Conﬁrmed Viral Failure after the First Episode of Viremia.
Of the 137 patients with at least one viremic episode, 15
(10.9%) were excluded from this analysis because their ﬁrst
viremic episode occurred on their last available visit. As
shown in Table 2(a), we did not ﬁnd diﬀerences in the
proportion of patients with a consecutive subsequent VL
≤1,000 (n = 37, 72.5% versus n = 41, 57.8%), 1,000–10,000
(n = 3, 5.9% versus n = 5, 7.0%), and >10,000 (n = 11,
21.6% versus n = 25, 35.2%) (P value = .166) in patients
with a ﬁrst episode of intermediate and high viremia.
3.5. Switch to Second Line. Reassuringly, none of the patients
with sustained suppression were switched to second line.
Interestingly, a higher proportion of patients with a ﬁrst
episode of intermediate viremia (n = 21, 39.6%) as
compared to patients with a ﬁrst episode of high viremia
(n = 16, 19.1%) were switched to second line treatment
(P = .008).
In a subanalysis, we also evaluated the outcomes of
51 (9.1%) patients that had a ﬁrst episode of viremia
between 400 and 1000 copies/mL; clinical and immunolog-
ical outcomes were similar to patients with sustained viral
suppression below 400 copies/mL. only 5 had a subsequent
conﬁrmed viral failure.
3.6. Recategorizing PatientsUsing 5,000 Copies/mL asa Cutoﬀ.
Thirty-seven of the 473 (7.8%) total patients had a ﬁrst
viremic episode between 1,000 and 5,000 copies/mL after a4 AIDS Research and Treatment
Table 2: Comparison of the subsequent viral load measurement in patients with a ﬁrst episode of viremia of 1,001–10,000copies/mL
and >10,000copies/mL. Comparison of the subsequent viral load measurement in patients with a ﬁrst episode of viremia of 1,001–
5,000copies/mL and >5,000copies/mL.
(a)
First episode of viremia (copies/mL) Number of patients∗ Subsequent viral load (copies/mL)
≤1,000 1,001–10000 >10000 P value
1,001–1,0000 51 37 (72.5) 3 (5.9) 11 (21.6) .166
>10000 71 41 (57.8) 5 (7.0) 25 (35.2)
∗Viral load was available for 122/137 (89.1%) patients with a ﬁrst episode of viremia.
(b)
First episode of viremia (copies/mL) Number of patients∗ Subsequent viral load (copies/mL)
≤1,000 1,000–5,000 >5,000 P value
1,001–5,000 37 30 (81.1) 1 (2.7) 6 (16.2) .017
>5,000 85 47 (55.3) 4 (4.7) 34 (40.0)
∗Viral load was available for 122/137 (89.1%) patients with a ﬁrst episode of viremia.
mediantimeof60weeks(IQR:26–96)and85(18%)patients
had a ﬁrst viremic episode >5,000 copies/mL after a median
time of 39 weeks (IQR: 25–74) (P = .331).
As expected, we found no diﬀerences in the proportion
of patients who died or developed opportunistic infections
across the 3 groups, and between patients with ﬁrst viremic
episode between 1,000–5,000 copies/mL and patients with a
ﬁrst viremic episode between 5,000–10,000 copies/mL.
The median CD4+ T-cell count increase at year 4 (or at
the last available observation) was higher in patients with
sustained suppression (186 cells/µL) compared to patients
with a ﬁrst viremic episode between 1,001–5,000 copies/mL
(167 cells/µL), and patients with a ﬁrst viremic episode
>5,000 copies/mL (100 cells/µL) (P<. 001). Interestingly,
patients with a ﬁrst episode of viremia between 1,000–
5,000copies/mL had a higher median increase in CD4+ T-
cell count as compared to patients with a ﬁrst episode of
viremia between 5,000 and 10,000 copies/mL (167 versus 52
cells/µL) (P<. 001). In addition, we found that patients
with a ﬁrst viremic episode >5,000 copies/mL had a lower
probability of reaching a CD4+ T-cell count of 200 cells/µL
as compared to either patients with sustained suppression
or patients with a ﬁrst viremic episode between 1,001–
5,000copies/mL (P = .017). However, the probability of
reaching a CD4+ T-cell count of 200 cell/µLb yy e a r4w a s
similar in patients with a ﬁrst viremic episode between 1,000
and 5,000 and in patients with viremia between 5,000 and
10,000 (P value = .35).
As shown in Table 2(b) a higher proportion of patients
with a ﬁrst viremic episode between 1,001–5,000 copies/mL
had a consecutive subsequent VL ≤1,000 copies/mL as
compared with patients with viremia >5,000 copies/mL
(81.1% versus 55.3%) (P value = .017).
While the proportion of patients that needed to be
switched to second line did not diﬀer statistically (P = .293)
between the patients with a ﬁrst episode of viremia between
1,001 and 5,000 copies/mL (33.3%) and those with a ﬁrst
episode of viremia >5,000 copies/mL (24.5%) (P = .293).
4.Discussion
In our cohort, the majority of the patients (71%) achieved
sustained suppression deﬁned as a VL ≤1,000 copies/mL
at each visit throughout the study period. Overall, patients
with a ﬁrst episode of intermediate and high viremia do
not experience in the medium term (4-year followup) more
O I so rd e a t h sa sc o m p a r e dt op a t i e n t st h a ta c h i e v es u s t a i n e d
suppression.
Despite the WHO recommendation to switch patients to
second line ART if the viral load exceeds 10,000copies/mL,
patients with viremic episodes between 1,001–10,000
copies/mL need to be closely followed because they have an
impaired CD4+ T-cell count rise as compared to patients
with sustained suppression. Moreover, the long-term conse-
quences of keeping patients on ﬁrst line with these levels of
viremia on morbidity and mortality are not known.
Whenwe analyzed theVL obtainedafter aﬁrst episodeof
viremia, we found that the majority of the patients with high
(72.5%) and intermediate (57.8%) viremia subsequently
achieved viral suppression. In our clinic, patients with viral
failure receive counseling to re-enforce adherence on their
following monthly routine visit, so that VL rebound can
be reversed in patients with virus susceptible to the same
antiretroviral treatment.
Conversely, 21.5% of the patients with viremia between
1,001–10,000 copies/mL, who should be kept on ﬁrst-line
therapy according to the 2006 WHO criteria, experienced a
subsequent conﬁrmed viral failure.
In our study, a higher proportion of patients with a
ﬁrst episode of intermediate viremia as compared to ones
with a ﬁrst episode of high viremia were later judged by
the clinicians to be in need of second line treatment. An
analysis from the UK Collaborative HIV Cohort Study [12]
showed that mutations are more frequent in resistance
tests performed at VLs between 300 to 10,000 copies/mL
and decrease at VLs above 10,000. It is likely that ﬁrst
episodesofveryhigh levelsofviremia inourcohortoccurred
in patients that had discontinued medications withoutAIDS Research and Treatment 5
clinicians’ knowledge and that, in the long run, manage to
achievesuppressionafteradherencecounseling.Ontheother
hand, a ﬁrst presentation with intermediate viremia could
be a sign of emerging drug resistance and, therefore, these
patients are likely to experience a subsequent detectable viral
load and increasing VL over time.
Because of the new WHO recommendations [9], we
also analyzed the treatment outcomes using a cutoﬀ of
5,000copies/mL. Patients with a ﬁrst episode of viremia
between 1,001–5,000 copies/mL do not seem to have an
impaired immune reconstitution; moreover, more than 80%
o ft h ep a t i e n t si nt h i sg r o u ph a v eas u b s e q u e n tV L≤1,000
copies.
Despite the newer guidelines provided by WHO, moni-
toring ART in resource limited settings is still very challeng-
ing. Previousresearch has shown thatthe currently proposed
criteria for assessing treatment failure using immunologic
response in the absence of a VL performs poorly in
cohorts from resource limited settings, and researchers are
advocating for accessible and cheap VL testing [13–17].
However, the ideal timing for VL testing is unclear. Some
suggestedstrategiesare toperformVLsonpatientssuspected
to be failing before switching to second line [18], or as an
adherence assessing strategy [19].
Our study suggests that one VL is not enough to make
a clinical decision on whether to switch treatment to second
line. In this cohort in Uganda, almost 60% of the patients
with high viremia (>10,000 copies/mL) will subsequently
achieve sustained suppression and only 19% were ultimately
judged by the clinicians to be in need of second line. This
study shows that the use of subsequent VLs measurement to
identify patients failing ART could have averted 60% to 80%
of unnecessary switches to second-line treatment. While the
new cutoﬀsuggested by the WHO seems to correctly identify
patients that can be still kept on ﬁrst-line, only a minority
of patients with a ﬁrst episode of any level of viremia had a
persistently detectable VL that prompted our physicians to
switch the patients to second line therapy.
Our study has some limitations. First, the follow-up
time after patients had a ﬁrst viremic episode may not have
been long enough to show the eﬀects on morbidity and
mortality ofremaining onaﬁrst line regimen withdetectable
viremia. The other limitation of the study is that that
we do not perform routine genotype resistance testing on
detectable samples; therefore, we do not know the eﬀect on
the accumulation of resistance mutations in these patients.
In conclusion, although the long-term consequences of
keepingpatients with detectableviremia on ﬁrst-line therapy
on clinical eventsare not known, in resource-limited settings
clinicians must weigh the risk of incurring viral resistance
in patients with a detectable VL against the high cost of
second line ART [20] and the relatively high proportion
of patients in our study who subsequently suppressed
with adherence counseling. Strong consideration should be
given to adherence counseling after the ﬁrst detectable viral
load and a repeated measurement of VL before switching
these patients to a second-line regimen in resource limited
settings.
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